Chemicals, Materials, and Formulations IP Toolkit: Claims, Data, Secrecy, and Regulatory Files

By Casey Scott McKay · 2026-06-18

Chemical and materials inventions are claimed in structures, ranges, and functional properties, and each of those raises a scope problem the mechanical arts do not have. This toolkit collects the recurring analysis. It works through genus and species claiming, Markush groups, the obviousness of ranges and structurally similar compounds, and the unexpected results showing that carries most of the prosecution. It then addresses the disclosure question that decides how broad a claim survives, the choice between patenting a formulation and keeping it secret, and the regulatory filings that disclose composition to an agency and sometimes to the public. It closes with freedom to operate in a field where a competitor's genus claim may cover a compound nobody has ever made.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 18 June 2026 - Updated 29 July 2026 | Casey Scott McKay - marksy.us

Summary. Chemical and materials inventions are claimed in structures, ranges, and functional properties, and each raises a scope problem the mechanical arts do not have. This toolkit works through genus and species claiming, Markush groups, the obviousness of ranges and structurally similar compounds, and the unexpected results showing that carries most of the prosecution. It addresses the disclosure question that decides how broad a claim survives, the choice between patenting a formulation and keeping it secret, and the regulatory filings that disclose composition to an agency and sometimes to the public. It closes with freedom to operate in a field where a competitor's genus claim may cover a compound nobody has ever made.

Keywords: chemical patent toolkit · Markush claims · genus and species · unexpected results · enablement and written description · formulation trade secrets · TSCA confidential business information · freedom to operate in chemistry · prophetic examples · obviousness of ranges · structural similarity · safety data sheets · regulatory disclosure · materials characterisation · process claims

Start Here

A chemist writes down a structure with variable positions, and a patent attorney turns it into a claim covering ten to the sixth compounds, of which four have ever been made.

That sentence contains the whole of this field's tension. The scope a chemical claim can reach is enormous, the data supporting it is finite, and the doctrines that police the gap — enablement, written description, and obviousness — do more work in chemistry than anywhere else in patent law.

Three problems recur.

Scope. How broad a genus can be claimed on how many worked examples, and what happens when a competitor practises within the genus at a point the specification never described.

Data. What has to be in the specification at filing, what can be supplied afterwards in a declaration, and what a range claimed without data across it is actually worth.

Secrecy. Whether to patent a formulation at all, given that patenting publishes a recipe that is frequently undetectable in the product, and given that the alternative — trade secret — is undone by the regulatory filings the product requires anyway.

This toolkit works those three in order, then adds the regulatory disclosure layer that distinguishes chemistry from every other technical field, and closes on freedom to operate.

Genus, Species, and the Markush Group

A Markush claim recites a group of alternatives: a core structure with substituent positions, each position selected from an enumerated list. It is the standard vehicle for chemical claiming and it is where the scope fight lives.

Breadth is a function of the lists. A claim with five variable positions and twenty alternatives at each covers millions of compounds, almost none of which has been synthesised.

Two doctrines police it. 35 U.S.C. § 112(a) requires a written description showing possession of the claimed invention and an enabling disclosure permitting a skilled artisan to make and use it without undue experimentation. In chemistry these are not formalities: a genus described only by formula, with three examples clustered at one corner, is vulnerable across the rest of its scope.

The Wands factors from In re Wands, 858 F.2d 731 (Fed. Cir. 1988), structure the undue experimentation analysis: quantity of experimentation, guidance, working examples, nature of the invention, state of the art, skill level, predictability, and claim breadth. Chemistry is an unpredictable art, which cuts against broad claims supported by little data.

And Amgen tightened it. Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), held that a claim defining a genus by function must enable the full scope, and that a disclosure of a research plan or a roadmap for finding further members does not enable the genus. The decision was about antibodies and its reasoning reaches every functionally defined genus in chemistry.

The practical drafting response is a nested claim set: a broad genus, several intermediate subgenera clustered around the data, a set of preferred embodiments, and specific species claims on the compounds actually made and tested. The broad claim may fall; the intermediate claims are what survive, and they are the ones that have to be drafted with real care rather than as an afterthought.

Obviousness in Chemistry

Structural similarity creates a prima facie case. A compound structurally close to a prior art compound is presumptively obvious where the art provides a reason to make the modification and a reasonable expectation of success — the framework of KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), applied to the lead compound analysis chemistry developed independently.

The lead compound analysis asks two questions. Would a skilled artisan have selected this prior art compound as a lead, and would they have had a reason to modify it in the way claimed with an expectation of success? Attacking the first question is frequently the better defence, because a compound selected with hindsight from a large prior art genus is not a lead compound at all.

Ranges are presumptively obvious over overlapping prior art ranges. A claimed range that overlaps or is close to a disclosed range shifts the burden to the applicant, and the rebuttal is criticality: evidence that the claimed range produces a difference in kind rather than in degree.

Unexpected results is the central rebuttal, and it is where most chemical prosecution is won and lost. The showing must be commensurate in scope with the claim, must compare against the closest prior art, must be a difference a skilled artisan would find surprising, and must be supported by data rather than by attorney argument. The Graham framework from Graham v. John Deere Co., 383 U.S. 1 (1966), places this and the other secondary considerations in the analysis, and they carry real weight in chemistry.

Comparative data has to compare the right things. A showing against a distant prior art compound, or against a commercial product rather than the closest disclosure, is routinely disregarded, and the examiner will say so.

Watch the scope match. Data on three species does not rebut obviousness across a genus of thousands, and an applicant who insists on the broad claim while submitting narrow data usually ends with neither.

The Disclosure Problem

What the specification contains at filing decides what the claims can cover, and chemistry punishes thin specifications more than any other art.

Working examples matter disproportionately. Actual syntheses, actual characterisation data, actual property measurements, spread across the claimed scope rather than clustered.

Prophetic examples are permitted and should be marked. A constructive example written in the present or future tense is acceptable practice; one written in the past tense as though it had been performed is a candour problem under 37 C.F.R. § 1.56 and a credibility problem in litigation.

Characterisation belongs in the specification. Spectra, purity, melting points, crystal forms, and analytical methods, because a compound the specification cannot distinguish from its neighbours is a compound the claim may not clearly cover.

Definitions matter more than in other arts. Terms like "about," "substantially pure," "polymorph," and "derivative" are construed against the specification, and Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (2014), requires reasonable certainty about scope.

Post-filing data can support, but not supply, the disclosure. A declaration under 37 C.F.R. § 1.132 can rebut obviousness with comparative results; it cannot cure an enablement or written description gap, because the sufficiency of the disclosure is measured as of the filing date.

And the priority chain has to hold. Claims added later must be supported in the earliest application relied upon, and a genus expanded in a continuation beyond what the parent described loses the earlier date for the expanded portion — which in a crowded field is frequently fatal.

Formulation, Process, and What to Keep Secret

Not everything should be patented, and formulation is the clearest case.

Ask the detectability question first. Can a competitor determine, from the product, that your process or composition was used? Modern analytical chemistry can reverse-engineer a great deal, and that fact cuts in favour of patenting — because a secret that can be read off the product is not a secret.

Where the answer is no, patenting publishes a recipe in exchange for a right that cannot be policed, and Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470 (1974), confirms that trade secret protection is an available and legitimate alternative.

Process conditions are the classic secret. Temperature profiles, addition rates, mixing regimes, catalyst loadings, and work-up procedures rarely leave a signature in the product and are frequently the difference between a yield that is commercial and one that is not.

Formulations are mixed. The identity of ingredients is often determinable; the ratios, the order of addition, and the processing conditions frequently are not.

The trade secret route requires real measures. 18 U.S.C. § 1839 conditions protection on reasonable measures, which means access segregation, marking, confidentiality obligations reaching contract manufacturers and individuals, and a register of who holds what.

And it requires attention to the departure risk, because the people who know a process take it with them, and the Defend Trade Secrets Act action that follows is expensive and uncertain.

Publish defensively where neither route fits. A defensive publication makes the subject matter prior art under 35 U.S.C. § 102, preventing a competitor from patenting it, at the cost of any exclusivity — which is the right answer for improvements that are neither commercially critical nor worth a filing.

The Regulatory Disclosure Layer

Chemistry is the field in which a company must tell a government what its product contains, and this interacts with secrecy in ways that surprise practitioners from other technical areas.

Substance notification. New chemical substances are notified to regulators before manufacture or import, with composition data, uses, and exposure information supplied. Confidential business information may be claimed, and the claim must be substantiated and periodically re-asserted; identities not successfully claimed as confidential appear on public inventories.

Safety data sheets disclose hazardous components with concentration ranges, and while trade secret withholding is available for some ingredients, the ranges disclosed frequently narrow the field enough to matter.

Ingredient labelling regimes in cosmetics, food, cleaning products, and consumer goods require disclosure at varying levels of specificity, and some jurisdictions require full ingredient listing where others permit "fragrance" or "flavour."

Registration dossiers in some jurisdictions require substantial data on identity, properties, and toxicology, held by the agency with limited public access and shared among registrants under data-sharing obligations.

Pesticide, biocide, and drug approvals each carry their own disclosure and data protection regimes, including regulatory exclusivity periods that function as an intellectual property right independent of patents.

Three practical points follow.

Coordinate the filings with the patent programme. A regulatory submission describing a composition can be prior art or a public disclosure depending on its treatment, and a filing calendar that ignores the regulatory calendar produces avoidable losses of novelty.

Substantiate confidentiality claims properly and diarise their renewal. A lapsed claim publishes an identity permanently.

And treat data protection as an asset. Regulatory data exclusivity, where available, protects a dossier that cost more than the patent programme and is frequently the real barrier to entry.

Freedom to Operate in a Crowded Genus

A chemical freedom to operate opinion is harder than a mechanical one, because a competitor's genus claim may cover a compound the competitor never made and never contemplated.

Search by structure, not only by keyword. Substructure and similarity searching across patent chemistry databases is the only reliable method, and a text search will miss a Markush claim that covers the compound of interest.

Analyse the claim as construed, not as summarised. A Markush group is read literally; the question is whether the compound falls within the enumerated alternatives at each position.

Consider the ranges. Composition claims with concentration ranges, process claims with condition ranges, and property-defined claims all require the actual product and process to be compared against the numbers.

Assess validity where coverage is found, because a genus claim covering a compound never described is precisely the claim most vulnerable under 35 U.S.C. § 112 after Amgen.

Consider design-around at the structural level. Substituting a position outside the enumerated list, changing a ratio outside a claimed range, or altering a process condition are often achievable, and the chemistry team should be given the claim rather than a summary of it.

Document the analysis with counsel, because an opinion supports the good faith showing relevant to willfulness under 35 U.S.C. § 284, and because privilege over the analysis matters if the question is later litigated.

And re-run it at scale-up. A freedom to operate opinion on a laboratory process is not an opinion on the commercial process, and the process is where the claims frequently bite.

Materials, Polymers, and Property-Defined Claims

Materials claims frequently define the invention by property rather than by structure — a modulus range, a melt flow index, a particle size distribution, a crystallinity — and this creates two specific problems.

Definiteness. A property claim requires a specified measurement method, because different methods give different numbers and Nautilus demands reasonable certainty. A claim to a modulus without a test standard is an invitation to an indefiniteness challenge.

Enablement across the property range. A claim to a material with a property between two values, supported by examples at one end, faces the Amgen problem in a different guise: the specification must enable the full range, not merely identify a target.

Polymers add their own dimensions: molecular weight distribution, tacticity, comonomer content and distribution, branching, and end groups, each of which may be claimed and each of which requires a stated method.

Composites and formulated materials are claimed as combinations with ranges, and the obviousness analysis over overlapping prior art ranges is the recurring fight.

Product-by-process claims are available where a product cannot otherwise be defined, with the well-known asymmetry: the process limitation is generally not given patentable weight for novelty and obviousness, but must be met for infringement. That asymmetry makes them weaker than they look, and they should be a fallback rather than a strategy.

And characterisation data belongs in the specification, because a materials claim the specification cannot support with measured values across the range is a claim that will not survive its first serious challenge.

Building the Programme

Run an invention harvest that captures process as well as product. Chemists report compounds; the process improvements that make them manufacturable are frequently never disclosed to the patent function at all, and they are often the more valuable asset.

Decide route by detectability, not by habit. Product claims where the product is the invention; process claims where the process leaves a signature; secrecy where it does not; defensive publication where neither is worth funding.

Build the data before filing where the schedule permits, because the specification is fixed at filing and post-filing declarations cannot cure a disclosure gap.

Draft nested claim sets — genus, subgenera around the data, preferred embodiments, and species — and treat the intermediate claims as the ones that matter.

Mark prophetic examples, define terms, and specify measurement methods for every property recited.

Coordinate the regulatory calendar with the filing calendar, and substantiate and diarise every confidentiality claim.

Operate the trade secret programme properly if secrecy is the chosen route, with access segregation, marking, contractor and individual obligations, and departure controls.

Run structural freedom to operate searches at candidate selection, at development milestone, and again at commercial scale-up.

And review the portfolio against the product line annually, pruning genus claims that no longer cover anything the business sells and maintaining the species claims that do.

A Worked Example

A speciality materials company develops a coating whose performance depends on a narrow additive concentration and a specific cure profile.

The additive is a known compound, so a compound claim is unavailable. A composition claim reciting the concentration range is available but faces overlapping prior art ranges, and rebuttal depends on a criticality showing supported by data at, above, and below the range.

The cure profile is the real invention and it is not detectable in the finished coating. Patenting it would publish the only thing a competitor cannot easily work out, in exchange for a right the company could not police.

So the programme splits. File the composition claim with the criticality data and a nested set of narrower ranges; keep the cure profile as a trade secret with segregated access, contractor obligations, and equipment-level controls; and publish defensively the incidental process improvements that neither justify a filing nor need protecting.

The regulatory layer then intrudes. Notification requires disclosure of the composition, and the confidentiality claim over the additive identity must be substantiated and renewed. The safety data sheet will disclose a concentration range for the hazardous component — and if the range disclosed is narrow enough, it may effectively publish the claimed range. That interaction should be modelled before the filing strategy is fixed, and it almost never is.

And freedom to operate closes the loop. A structural search identifies a competitor's genus claim covering the additive in a coating context, drafted broadly on three examples in a different application. The advice is a validity assessment under Amgen and section 112, a design-around option outside the enumerated substituents, and a documented opinion — in that order.

Eligibility, Which Bites Less Here Than Elsewhere

Chemistry is largely spared the abstract idea problem that dominates software patenting, but 35 U.S.C. § 101 still has two edges in this field.

Natural products. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), held that isolated naturally occurring material is not patent eligible merely by virtue of isolation, while a synthetic construct with markedly different characteristics is. The practical line is markedly different characteristics, and a purified natural extract with the same structure and function as the source material is on the wrong side of it.

Natural laws and correlations. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), invalidated claims reciting a natural correlation plus conventional steps, and diagnostic and method-of-treatment claiming in chemistry has been shaped by it ever since.

Method of treatment claims remain eligible, which is why the drafting response in pharmaceutical chemistry is frequently a method of treatment claim rather than a claim to a correlation.

Compositions with new properties are safe. A formulated composition with characteristics the components do not have individually is a manufacture rather than a natural product, and the specification should make the differences explicit rather than assuming they are obvious to the reader.

And where a natural material is the starting point, plan the claim set around the modification, the formulation, the process, and the use — because the isolated material itself is unavailable.

Prosecution Strategy in Practice

Restriction and unity practice shapes the family. Compound, composition, process of making, and method of use are frequently restricted into separate applications, and the divisional strategy should be planned at filing rather than reacted to at the first office action.

File the priority application with the data you have and continue. Chemistry programmes generate data continuously, and a continuation-in-part adding new examples gets the earlier date only for what the parent supported — so the calendar matters more than the drafting.

Use the examiner interview. Chemical rejections turn on comparative data and on what the closest prior art actually teaches, and both are far more efficiently resolved in a conversation than across three written rounds.

Prepare the declaration carefully. A 37 C.F.R. § 1.132 declaration must compare against the closest prior art, cover the claimed scope, and be signed by someone with the relevant expertise. Declarations that compare against a commercial product rather than the reference are the most common wasted filing in this field.

Watch prosecution history estoppel. Narrowing amendments surrender equivalents under Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002), and in chemistry an amendment narrowing a range or removing a substituent forecloses the doctrine of equivalents argument that Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 520 U.S. 17 (1997), would otherwise permit for insubstantial differences.

Draft with claim construction in mind. Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc), makes the specification the primary source, so define the terms you care about and do not rely on ordinary meaning for anything load-bearing.

And keep the candour file. 37 C.F.R. § 1.56 obligations reach comparative data known to the applicant, and adverse results withheld while favourable results are submitted is the fact pattern that produces inequitable conduct allegations.

Collaboration, Toll Manufacture, and Joint Development

Chemistry is collaborative — with universities, with contract research organisations, with toll manufacturers, and with customers — and each relationship carries an ownership question the parties resolve badly.

Joint development agreements should allocate background, foreground, and improvements separately, and should say what happens to jointly conceived subject matter. Under United States law each joint owner may exploit and licence without accounting to the other, which is almost never what the parties intend and is the default they get if the agreement is silent.

Inventorship is not negotiable. It is determined by contribution to conception of a claimed invention, and an agreement purporting to allocate inventorship rather than ownership is void as to the former. Get the assignment right and the inventorship determination correct, separately.

Contract research organisations typically own nothing by contract and everything by default absent an assignment, and their personnel are the ones in the laboratory.

Toll manufacturers develop process improvements as a matter of course, and the three-bucket improvements approach — customer design, supplier general capability, joint — is the workable allocation.

Universities bring publication obligations, government funding conditions, and institutional policies that override individual agreements, and the publication timetable is the one that most often destroys foreign novelty under 35 U.S.C. § 102.

Materials transfer agreements impose downstream obligations that survive the transfer and travel with any compound derived from the material, and they are signed by scientists without review with striking regularity.

Address the data too. Analytical data, screening results, and negative results all have value, and an agreement that allocates inventions and says nothing about data has allocated the smaller asset.

What Clients Actually Ask

"How broad can we claim?" As broad as the data supports plus a reasonable extrapolation in a predictable direction, and no broader after Amgen. The useful answer is a nested set rather than a number.

"Can we file now and add the data later?" You can file a declaration later to rebut obviousness. You cannot cure a section 112 gap later, because sufficiency is measured at the filing date.

"Should we patent the process?" Only if infringement would be detectable from the product. If not, publishing the recipe buys a right you cannot enforce.

"Is our formulation a trade secret if the label lists the ingredients?" The identities are not, the ratios and the process may be, and the analysis has to be done ingredient by ingredient against what the regulatory filings actually disclose.

"Their patent covers a compound they never made — is that valid?" Possibly not, and a genus claim covering undescribed subject matter is the most vulnerable claim in chemistry. Assess it rather than assuming either way.

"Can we get around a range?" Frequently, and the chemistry team should be given the actual claim language rather than a summary, because the design-around lives in the enumerated alternatives and the endpoints.

"What is our biggest exposure?" Usually a process secret held by six people, none of whom has signed anything specific, in a business that believes its patents are the protection.

Scale and Cadence

A start-up with one platform chemistry needs inventor assignments, a filing on the core with a nested claim set, a detectability assessment on the process, and nothing else.

A mid-sized speciality business needs the invention harvest extended to process, a combined register of patents, secrets, publications, and confidentiality claims, freedom to operate at each development milestone, and a trade secret programme that can evidence reasonable measures.

A large chemical company needs all of that plus coordination between the patent calendar and the regulatory calendar, portfolio pruning against the current product line, and a collaboration template that allocates background, foreground, improvements, and data consistently across dozens of agreements.

Review annually, and on five triggers: a scale-up, a new regulatory filing, a new collaboration, a competitor's publication in the same structural space, and the departure of anyone on the process access list.

Why This Field Is Different

Chemistry is the only technical area in which the claim can cover more than has ever existed. A Markush group describes a possibility space, and the patent system's bargain — disclosure for exclusivity — becomes strained when the disclosure covers four compounds and the exclusivity covers a million.

The doctrines that police that strain are old and have recently tightened. Enablement and written description have been in the statute since 1952 and were, for decades, applied lightly in chemistry. Amgen changed the temperature, and the effect is being felt in prosecution rather than only in litigation.

Secrecy is more viable here than almost anywhere. A process condition that leaves no trace in the product is genuinely protectable indefinitely, and the trade-off against a twenty-year unenforceable monopoly is a real strategic choice rather than a theoretical one.

And the regulatory system is a second, parallel intellectual property regime. Data exclusivity, dossier protection, confidentiality claims, and inventory listings determine market access independently of any patent, and a portfolio strategy that ignores them is describing half the position.

Which is why the advice in this field is rarely "file a patent." It is: assess detectability, allocate the invention across patents, secrets, and publications, coordinate with the regulatory calendar, and build the data that makes the chosen route defensible — and then file the right thing.

A Ninety-Day Programme

Days one to fifteen. Harvest inventions across product and process, and run a detectability assessment on each: could a competitor determine from the product that this was used?

Days fifteen to thirty. Build the combined register — patents, applications, defensive publications, trade secrets, and regulatory confidentiality claims — with owners, dates, and renewal obligations against each.

Days thirty to forty-five. Map the data. Which examples support which claim scope, where the gaps are, and what experiments would close them. This is the document that determines what can honestly be claimed.

Days forty-five to sixty. Audit the trade secret measures: access lists, segregation, marking, contractor and individual obligations, and departure controls. Test them against the 18 U.S.C. § 1839 standard rather than against internal comfort.

Days sixty to seventy-five. Reconcile the patent and regulatory calendars. Identify every confidentiality claim needing substantiation or renewal, and every regulatory submission that could constitute a disclosure.

Days seventy-five to ninety. Run structural freedom to operate on the current commercial range and on the next two development candidates, and record the opinions.

Then run annually, with the data map, the secret access review, and the confidentiality claim calendar as the recurring items — and the freedom to operate refresh at every scale-up.

Enforcement, Briefly

Chemical infringement is proved by analysis, which makes the evidence question unusually tractable and the access question unusually hard.

Obtain the accused product lawfully and characterise it against the claim elements, with a documented chain of custody and a method the other side's expert can replicate.

Process claims are the difficulty. Infringement of a process claim must be proved from the product or from discovery, and where the process is practised abroad, 35 U.S.C. § 271(g) reaches the importation of the resulting product — one of the more useful provisions in this field and one of the least used.

Marking matters for damages. 35 U.S.C. § 287 conditions pre-suit damages on marking or actual notice, and chemical products are marked inconsistently because the "product" is frequently a drum, a tanker, or a bulk delivery.

Doctrine of equivalents is narrower than clients hope. Warner-Jenkinson permits insubstantial differences, and Festo forecloses equivalents surrendered by narrowing amendment — which in chemistry usually means the range endpoints and the substituent list are literal boundaries.

And in a trade secret case, identification is the threshold. A plaintiff asserting a process secret must identify it with reasonable particularity before discovery proceeds in most courts, and the identification frequently reveals that what was actually protected is narrower than what was believed.

A Closing Note

The characteristic mistake in chemical intellectual property is a portfolio built entirely of compound claims.

It is the natural instinct. The chemists invent compounds, the compounds are the visible output, and a compound claim is the cleanest thing a patent attorney can draft. So the filings go on the molecules, the process work is never disclosed to the patent function, the formulation is assumed to be covered, and the regulatory confidentiality claims are handled by a different department entirely.

Then the product launches, and the position turns out to be: a compound claim on a molecule a competitor can design around at one substituent; no process protection, because the process was never captured; a formulation whose ratios are disclosed in the safety data sheet; and a confidentiality claim over the additive identity that lapsed two years ago because nobody renewed it.

Every element of that failure is preventable and none of it is doctrinal. It is a harvesting problem, a detectability assessment nobody ran, and two calendars that were never reconciled.

Which makes the highest-value work in this field unglamorous. Ask the chemists what makes the process work. Ask whether a competitor could tell. Ask what the regulatory filings will disclose and when. Then decide what to patent, what to keep, and what to publish — and file accordingly.

Those four questions take an afternoon with the technical team, and they change the shape of a portfolio more than any amount of drafting skill applied afterwards.

And they are questions a lawyer can ask without being a chemist, which is worth saying to practitioners who avoid this field because the technology intimidates them. The technical judgement belongs to the client; the questions that surface it belong to counsel.

A practitioner who asks them well will produce a better portfolio than one who knows the chemistry and never asks at all.

That is the argument for treating this toolkit as a set of prompts rather than as a body of doctrine to be mastered before use.

A Suggested Reading Path

Start with the doctrine in Claiming a Compound.

Then the practice in Protecting a Chemical or Materials Invention.

Then the audit in the chemical and materials IP checklist.

For the disclosure doctrines, The Bargain of Disclosure and the section 112 compliance checklist.

For prosecution mechanics, Inside Patent Prosecution and the Patent Prosecution Toolkit.

For the biological analogue, Claiming Life and the Biotechnology and Synthetic Biology IP Toolkit.

For the secrecy route, Trade Secrets and the DTSA and the Trade Secret Protection Toolkit.

For clearance, the Freedom to Operate and Patent Clearance Toolkit.

For the regulated life sciences overlay, the Life Sciences Patent Toolkit and The Dance Before the Drug.

And for supply chain secrecy, the Contract Manufacturing, OEM, and Private Label IP Toolkit.

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 101 | Eligible subject matter; natural products | | 35 U.S.C. § 102 | Novelty; grace period; defensive publication | | 35 U.S.C. § 103 | Obviousness | | 35 U.S.C. § 112 | Written description; enablement; definiteness | | 35 U.S.C. § 271 | Infringement; process claims and imports | | 35 U.S.C. § 284 | Damages; enhancement | | 35 U.S.C. § 287 | Marking and notice | | 18 U.S.C. § 1839 | Trade secret definition; reasonable measures | | 18 U.S.C. § 1836 | DTSA civil action | | 37 C.F.R. § 1.56 | Duty of candour | | 37 C.F.R. § 1.132 | Declarations rebutting rejections | | Amgen Inc. v. Sanofi | Enablement of a functionally defined genus | | In re Wands | Undue experimentation factors | | KSR International v. Teleflex | Obviousness framework | | Graham v. John Deere | Obviousness findings and secondary considerations | | Nautilus v. Biosig Instruments | Definiteness; reasonable certainty | | Kewanee Oil v. Bicron | Trade secret coexists with patent | | Association for Molecular Pathology v. Myriad Genetics | Isolated natural products | | Mayo Collaborative Services v. Prometheus Laboratories | Natural law and eligibility | | Festo v. Shoketsu Kinzoku Kogyo Kabushiki | Prosecution history estoppel | | Warner-Jenkinson v. Hilton Davis Chemical | Doctrine of equivalents | | Phillips v. AWH Corp. | Claim construction; intrinsic evidence | | Bonito Boats v. Thunder Craft Boats | Preemption of state anti-copying rules | | TSCA confidential business information claims | Substantiation and renewal of confidentiality | | Safety data sheet trade secret withholding | Disclosure of hazardous components | | Regulatory data exclusivity | Protection independent of patents |

Forms and Templates

The Assignment Agreement Template covers inventor and contractor assignments, and in chemistry it should be paired with a laboratory notebook and data retention policy, because the conception and reduction to practice records that support inventorship also support the unexpected results declarations that carry prosecution. The License Agreement Template supplies the structure for a materials supply, toll manufacturing, or joint development agreement, where the provisions that matter are the improvements buckets, the confidentiality obligations reaching individual operators, and the allocation of regulatory dossiers and data compensation rights. The Portfolio Inventory Template adapts into a combined register of patents, defensive publications, trade secrets, and regulatory confidentiality claims — which is the document this field actually needs and almost nobody maintains. Beyond those, keep four internal records: a detectability assessment per invention; a data map showing which examples support which claim scope; a confidentiality claim calendar; and a structural freedom to operate log refreshed at each development milestone.

Related Toolkits and Checklists

The Patent Prosecution Toolkit carries the procedural mechanics this toolkit assumes. The Biotechnology and Synthetic Biology IP Toolkit applies the same scope doctrines to sequences and deposits. The Trade Secret Protection Toolkit covers the alternative route for undetectable process knowledge. The Freedom to Operate and Patent Clearance Toolkit covers the structural searching this field requires, and the Life Sciences Patent Toolkit covers the regulatory exclusivity layer where the product is a drug.